Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study

被引：10
|
作者：
D'Amico, Emanuele [1 ]
Zanghi, Aurora [1 ]
Calogero, Aldo Eugenio [2 ]
Patti, Francesco [1 ]
机构：
[1] Univ Catania, Dept Med Surg Sci & Adv Technol GF Ingrassia, Via Santa Sofia 78, I-95123 Catania, Italy
[2] Univ Catania, Dept Clin & Expt Med, Catania, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 14期
关键词：
Multiple sclerosis; men fertility; gonadal steroids; ocrelizumab; natalizumab; SEMEN QUALITY; PREGNANCY; WOMEN;
D O I：
10.1177/13524585211009208
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Scarce data are available about the impact of natalizumab (NTZ) and ocrelizumab (OCR) on male fertility in relapsing-remitting multiple sclerosis (RRMS). In this case-control prospective study, the gonadal steroids and the sperm parameters have been analysed at the time of the RRMS diagnosis and after 12 months from the beginning of the investigated therapies. Sixteen men with RRMS and sixteen matched healthy controls were included. At enrolment and after 12 months on therapy, the gonadal steroids and the sperm parameters of men with RRMS did not differ from the healthy controls. In conclusion, therapy with NTZ and OCR had no impact on fertility status in our cohort of men with RRMS. Further randomized and prospective studies are needed.
引用
收藏
页码：2284 / 2287
页数：4
相关论文
共 50 条
  • [41] Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab
    Laursen, Julie Hejgaard
    Sondergaard, Helle Bach
    Sorensen, Per Soelberg
    Sellebjerg, Finn
    Oturai, Annette Bang
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 10 : 169 - 173
  • [42] Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis
    Bridel, Claire
    Leurs, Cyra E.
    van Lierop, Zoe Y. G. J.
    van Kempen, Zoe L. E.
    Dekker, Iris
    Twaalfhoven, Harry A. M.
    Moraal, Bastiaan
    Barkhof, Frederik
    Uitdehaag, Bernard M. J.
    Killestein, Joep
    Teunissen, Charlotte E.
    NEUROLOGY, 2021, 97 (19) : E1898 - E1905
  • [43] Clinical management of high-risk patients with relapsing-remitting multiple sclerosis (MS) treated with natalizumab
    Vo, K. H.
    Stazzone, L.
    Drago, N.
    Nguyen, H.
    Buckle, G.
    JOURNAL OF NEUROLOGY, 2013, 260 : S67 - S67
  • [44] Autoimmunity in patients treated with alemtuzumab for relapsing-remitting multiple sclerosis
    Fox, E. J.
    Arnold, D. L.
    Cohen, J.
    Coles, A. J.
    Confavreux, C.
    Hartung, H. -P.
    Havrdova, E.
    Selmaj, K.
    Weiner, H.
    Lake, S. L.
    Margolin, D. H.
    Oyuela, P.
    Panzara, M.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 465 - 466
  • [45] Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
    van Lierop, Z. Y. G. J.
    Toorop, A. A.
    Coerver, E. M. E.
    Willemse, E. A. J.
    Strijbis, E. M. M.
    Kalkers, N. F.
    Moraal, B.
    Barkhof, F.
    Teunissen, C. E.
    Killestein, J.
    van Kempen, Z. L. E.
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (02)
  • [46] Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Cohort Study
    Hernandez-Preciado, Martha Rocio
    Marquez-Pedroza, Jazmin
    Sanchez-Rosales, Nayeli Alejandra
    Garcia-Rivera, Jose de Jesus
    Kobayashi-Gutierrez, Antonio
    Torres-Mendoza, Blanca Miriam
    Chavarria-Avila, Efrain
    Montano-Serrano, Raul Alejandro
    Cortes-Enriquez, Fernando
    Mireles-Ramirez, Mario Alberto
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (13)
  • [47] Prospective Observational Study in a Cohort of Patients Affected by Relapsing-Remitting Multiple Sclerosis Treated with Dimethyl Fumarate
    Di Cristinzi, Maria
    Moiola, Lucia
    Pisa, Marco
    Sangalli, Francesca
    Dalla Costa, Gloria
    Radaelli, Marta
    Preziosa, Paolo
    Romeo, Marzia
    Boneschi, Filippo Martinelli
    Colombo, Bruno
    Esposito, Federica
    Martinelli, Vittorio
    Comi, Giancarlo
    NEUROLOGY, 2018, 90
  • [48] Real world experience with ocrelizumab in patiens with relapsing-remitting multiple sclerosis
    Lopez Ruiz, R.
    Dotor Garcia-Soto, J.
    Hiraldo, J. D. G.
    Ruiz-Pena, J. L.
    Paramo Camino, M. D.
    Ruiz De Arcos, M.
    Navarro Mascarell, G.
    Eichau Madueno, S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 301 - 301
  • [49] NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with ocrelizumab or natalizumab
    Signoriello, Elisabetta
    Schiavetti, Irene
    Bonavita, Simona
    Romano, Giuseppe
    Landi, Doriana
    Marfia, Girolama Alessandra
    Maniscalco, Giorgia Teresa
    Foschi, Matteo
    Pasquali, Livia
    Morra, Vincenzo Brescia
    Napoli, Francesca
    Caliendo, Daniele
    Abbadessa, Gianmarco
    D'Amico, Emanuele
    Lus, Giacomo
    Sormani, Maria Pia
    Signori, Alessio
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 638 - 639
  • [50] Ocrelizumab Alters the Circulating Metabolome in People with Relapsing-remitting Multiple Sclerosis
    Siavoshi, Fatemeh
    Ladakis, Dimitrios C.
    Muller, Ashley
    Nourbakhsh, Bardia
    Bhargava, Pavan
    ANNALS OF NEUROLOGY, 2024, 96 : S92 - S93
12345